Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION) (ACTION)

5 maggio 2026 aggiornato da: Faisal Sharif, University of Galway

Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes

The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.

The main questions it aims to answer are:

  • Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?
  • How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.

Participants will:

  • Provide informed consent and medical history/demographic information
  • Undergo blood sampling for cardiovascular and metabolic biomarkers
  • Have a resting ECG performed
  • Complete a detailed lifestyle and health questionnaire
  • Receive a non-invasive cardiac CT scan interpreted by an expert
  • Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality
  • Be referred for further clinical evaluation if clinically indicated 

Panoramica dello studio

Descrizione dettagliata

The ACTION Registry (Artificial Intelligence-assisted CT for Risk Stratification in Coronary Artery Disease) is a prospective, single-centre, observational patient registry conducted at the Clinical Research Facility, University Hospital Galway.

This registry is designed to systematically collect and integrate multimodal data from adults undergoing clinically indicated cardiac computed tomography (CT) to support advanced cardiovascular risk assessment using artificial intelligence (AI)-based approaches.

Registry Design and Procedures Eligible participants are consecutively enrolled at the time of referral for clinically indicated cardiac CT. Following informed consent, data are collected during a single baseline visit and supplemented by routine clinical data and follow-up information where available.

Registry procedures include:

  • Collection of demographic and clinical data from medical records
  • Blood sampling for cardiovascular and metabolic biomarkers
  • Resting electrocardiogram (ECG)
  • Structured questionnaires capturing lifestyle, cardiovascular history, and risk factors
  • Standard-of-care cardiac CT imaging acquisition and expert interpretation
  • Recording of medication use and clinically relevant interventions A subset of participants undergoing invasive imaging (e.g., optical coherence tomography) will have additional data collected for cross-modality comparison.

Data Collection and Registry Variables

The registry captures structured data across the following domains:

  • Clinical and demographic characteristics
  • Laboratory biomarkers
  • Imaging-derived parameters from cardiac CT
  • Lifestyle and behavioural factors
  • Treatment and medication data

All variables are defined in a standardized data dictionary, which specifies:

  • Variable definitions and formats
  • Source of data (e.g., imaging system, laboratory system, questionnaire)
  • Coding standards where applicable
  • Acceptable ranges and units Data Management and Quality Assurance All data are anonymised using unique participant identifiers and stored in secure, access-controlled electronic systems compliant with GDPR and institutional data governance policies.

A comprehensive quality assurance plan is implemented, including:

Data Validation and Entry Controls

  • Electronic data capture systems incorporate predefined validation rules
  • Range checks and logical consistency checks are applied at data entry
  • Automated queries are generated for missing, inconsistent, or out-of-range values Data Monitoring and Auditing
  • Periodic internal data reviews are conducted to ensure completeness and accuracy
  • Selected variables undergo source data verification against original records (e.g., imaging reports, laboratory systems, case report forms)
  • On-site or remote monitoring may be conducted in accordance with institutional policies Source Data Verification
  • A predefined proportion of records will be cross-checked with source documents
  • Discrepancies will be documented, reviewed, and resolved בהתאם standard procedures Standard Operating Procedures (SOPs)

Registry operations are governed by standardized procedures covering:

  • Participant recruitment and consent
  • Data collection and entry
  • Imaging acquisition and reporting
  • Laboratory data handling
  • Data management and security
  • Statistical analysis and reporting
  • Adverse event identification and reporting (if applicable)
  • Change management and protocol amendments Sample Size Considerations As an observational registry, the study aims to recruit a representative, real-world population of adults undergoing cardiac CT. The sample size is determined pragmatically based on recruitment feasibility and expected patient volume at the study site.

The anticipated sample size is sufficient to support:

  • Multivariable modelling for risk prediction
  • Subgroup analyses
  • Development and validation of AI-based models Handling of Missing Data

Missing or incomplete data may arise due to non-response, unavailable records, or technical limitations. The registry implements the following approach:

  • Real-time prompts to minimise missing data at entry
  • Documentation of reasons for missingness where available
  • Statistical handling using appropriate methods (e.g., multiple imputation, sensitivity analyses), depending on the extent and pattern of missing data Statistical Analysis Plan Analyses will be conducted in accordance with a predefined statistical analysis plan.

Approaches may include:

  • Descriptive statistics for baseline characteristics
  • Correlation analyses between imaging, clinical, and biomarker variables
  • Regression modelling for risk prediction and association analyses
  • Subgroup analyses across demographic and clinical strata
  • Cross-modality comparisons for imaging validation
  • Longitudinal analyses where follow-up data are available Model performance may be evaluated using appropriate metrics (e.g., discrimination, calibration, and reclassification measures).

Data Use and Future Applications

The registry is designed to support:

  • Clinical research and hypothesis generation
  • Development and validation of AI-based cardiovascular risk models
  • Integration of imaging and clinical data for precision medicine approaches An anonymised dataset will be maintained for future research, subject to governance and ethical approvals.

Ethical and Regulatory Considerations The registry is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval will be obtained from the appropriate research ethics committee, and all participants will provide written informed consent prior to inclusion

Tipo di studio

Osservativo

Iscrizione (Stimato)

10000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

All-comers adult population undergoing clinically indicated cardiac CT in routine clinical care

Descrizione

Inclusion Criteria:

  • Adults aged ≥18 years
  • Undergoing clinically indicated cardiac CT
  • Able and willing to provide informed consent

Exclusion Criteria:

  • History of malignancy
  • Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)
  • Contraindications to iodinated contrast agents or CT imaging

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cardiovascular risk stratification using AI-assisted cardiac CT
Lasso di tempo: Baseline
Assessment of cardiovascular risk based on AI-enhanced cardiac CT imaging, including coronary artery calcium scoring, plaque characterization, and integrated risk prediction using clinical and imaging data.
Baseline

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Correlation between CT-derived plaque characteristics and haematological biomarkers
Lasso di tempo: Baseline
Association between imaging-derived plaque features and blood biomarkers (e.g., CRP, lipid profile, ApoB/ApoA-1 ratio).
Baseline
Concordance between coronary CT angiography (CCTA) and optical coherence tomography (OCT)
Lasso di tempo: Baseline (subset undergoing OCT)
Agreement between CT-derived plaque characteristics and OCT findings in a subset of participants.
Baseline (subset undergoing OCT)
Association between lifestyle factors and imaging-derived plaque risk features
Lasso di tempo: Baseline
ssociation between lifestyle factors (e.g., smoking, diet, occupation) and imaging-derived Parameters.
Baseline
Subgroup analyses of cardiovascular risk by demographic and clinical factors
Lasso di tempo: Baseline
Differences in imaging and risk profiles across subgroups (age, sex, comorbidities, hormonal history).
Baseline
Longitudinal changes in plaque composition in patients receiving statin therapy
Lasso di tempo: Baseline, 1 year, and annually up to 5 years
Evaluation of plaque progression or regression over time in participants on statin treatment.
Baseline, 1 year, and annually up to 5 years
Feasibility and utility of CT-derived fractional flow reserve (CT-FFR) and AI-based risk models
Lasso di tempo: Baseline
Assessment of the applicability and performance of CT-FFR and AI-based models in risk prediction.
Baseline

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Development of an anonymized multimodal dataset for AI training and validation
Lasso di tempo: through study completion, up to 10 years
Creation of a secure dataset integrating imaging, clinical, biomarker, and lifestyle data for future AI development.
through study completion, up to 10 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Faisal Sharif, MBBS, PhD, FRCPI, FESC, FACC, University of Galway

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

21 dicembre 2022

Completamento primario (Stimato)

21 dicembre 2032

Completamento dello studio (Stimato)

21 dicembre 2032

Date di iscrizione allo studio

Primo inviato

28 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 maggio 2026

Primo Inserito (Effettivo)

11 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

11 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi